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of the study is that the safety data were obtained from clinical trials rather than 
actual clinical practice with these drugs.
PCV45
Estimating thE ValuE Of CangrElOr frOm Eliminating PrElOading in 
COrOnary artEry ByPass graft (CaBg) PatiEnts
Bay C., Cyr P.L., Jensen I.
ICON plc, Cambridge, MA, USA
Objectives: 2011 AHA and 2012 ESC guidelines recommend antiplatelet therapy 
at presentation for suspected ACS patients. For CABG patients (approximately 10% 
of ACS presentations) this strategy creates a dilemma: delay CABG to washout anti-
platelet therapy or perform surgery and risk bleeding. Bridging strategies have been 
proposed using GPIs. Cangrelor, a novel reversible, IV P2Y12 inhibitor with rapid 
onset/offset, demonstrated in the CHAMPION PHOENIX trial a reduction in ischemic 
events vs. clopidogrel in patients undergoing PCI. Adoption of cangrelor for angiog-
raphy in ACS patients eliminates the need to washout an oral P2Y12inhibitor in case 
of unanticipated CABG. The aim of our analysis was to quantify the annual value of 
this pathway change to a US hospital. MethOds: A decision analytic model based 
on the current CABG patient pathway was developed to quantify the value of a 
reduction in bridging by adopting cangrelor from a US hospital perspective. Premier 
hospital database informed the timing of CABG after washout; demographics, drug-
mix, LOS, blood product utilization, and hospital ward costs. Ischemic event rates 
and costs were informed by published sources. Drug costs were 2014 wholesale 
acquisition costs. Cangrelor cost was set to $0. Results: For a hypothetical US 
hospital treating 195 CABG patients/year (patient mix: 4% STE-ACS, 26% NSTE-ACS, 
70% SA), shifting away from bridging with GPI by adopting cangrelor resulted in a 
total annual cost reduction of $120,000. Total costs in the base-case are estimated 
to be $2.95MM vs. the scenario case of $2.83MM. Cost savings were derived from 
eliminating GPI utilization, lowering washout drug costs and reducing hospitaliza-
tion days. cOnclusiOns: Removal of the need to washout oral antiplatelet therapy 
prior to CABG through adoption of cangrelor is estimated to deliver a clinical value 
of ~$615/CABG patient with fewer total days spent hospitalized.
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Objectives: To analyse the budgetary impact (BI) of the introduction of NOAC 
in patients with NVAF compared to warfarin treatment scenario (DC) from the 
perspective of the public health system of Extremadura (PHSE). MethOds: 
A budget impact study was performed during 2013. It was based on anticoagulant 
therapy (AO) on patients with NVAF. The data came from the electronic clinical his-
tory called JARA®. Pharmaceutical costs associated to the control and monitoring 
of patients with DC were included. Specifically those related to the incidence of 
stroke (CVA), gastrointestinal haemorrhage (HG), intracranial haemorrhage (ICH) 
and acute myocardial infarction (AMI) as the RE-LY, ROCKET and ARISTOTLE trials. 
For DC, there were taken into account the best and worst scenario. The pharmaceu-
tical cost considered was the sum of the official price and the VAT. To other public 
health costs, official prices from the PHSE and the Spanish National Health Care 
System were considered. Results: Treatment distribution among patients was 
92.63% DC; 4.02% Dabigatran (DAB); 3.07% rivaroxaban (RIV) and 0.28% Apixaban 
(APX). The total expenditure for the AO patients with VKA in the best scenario is 
€ 3,036,604.28 (average cost per patient: € 342.11, CI 95%: 341.89 - 342.34) and the 
worst would be € 3,727,169 (€ 419.92, CI 95%: 419.70 - 420.15). For NOAC the results 
are € 572,515.39 (€ 810.93, CI 95%I: 786.71 - 835.16). NOAC represent the 71.44% of the 
pharmaceutical expenditure (PE), the 23.47% of PE’s control and monitoring of DC 
and the 15.86% of the total expenditure from AO patients with NVAF, in the best sce-
nario. cOnclusiOns: The market access of NOAC has been modest and similar to 
the rest of Spain. AVK alternative has the lowest average cost per patient. Limitation: 
safety data has been obtained from clinical trials instead of using clinical practice.
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Objectives: Updated treatment guidelines for atrial fibrillation (AF) have been 
released by the National Institute for Health and Care Excellence (NICE) in the 
United Kingdom and highlight a current shortfall in the prescribing of anticoagu-
lants to patients with AF despite the importance of stroke prevention. A model 
was designed for use as a planning tool for Clinical Commissioning Groups (CCGs) 
looking to budget for the future move towards full implementation of the NICE 
guidelines. MethOds: An Excel model was developed to estimate the 5-year 
impact of gradually treating all eligible AF patients who are currently not being 
prescribed anticoagulants, both in terms of the effect on clinical outcomes (strokes, 
major bleeds and mortality) and the financial impact associated with treating more 
patients. Assumptions had to be made in order to simplify the model and populate 
default values. Risks of clinical outcomes were taken from a literature search. Costs 
were taken from published national sources. Results: In an average sized CCG 
(population of 226,000) the model estimated that in order to gradually treat the full 
eligible AF patient population, an additional budget of £103,899 will be required in 
Year 1 to treat an additional 248 patients, rising to £791,076 in Year 5 to treat an 
additional 1,889 patients. Cumulatively over the 5-year timeframe this could lead 
to the prevention of 8 ischemic strokes and 3 deaths, as well as an increase of 2 
haemorrhagic strokes and 8 bleeds. cOnclusiOns: The clinical benefits of appro-
living and mobility. Botulinum neurotoxin-A (BoNT-A) injections are effective in 
treating ULS. We aimed to calculate annual BoNT-A treatment cost of ULS on a 
per-patient basis, and the expected overall annual budget impact of BoNT-A treat-
ment in Germany using static and dynamic market share scenarios. MethOds: 
A budget impact model for BoNT-A use, adopting a German health care system 
perspective, was developed. Two market-share scenarios were modelled over 5 years. 
While the static scenario assumed current market shares (abobotulinumtoxinA, 
36%; onabotulinumtoxinA, 26%; incobotulinumtoxinA, 38%) to remain constant over 
time, the dynamic scenario assumed market share of abobotulinumtoxinA to rise 
up to 76% across 5 years. Epidemiologic data inputs were sourced from the most 
recently published literature, unit costs for BoNT-As from the Lauertaxe (pharmacy 
purchase price [PPP] level), and market share assumptions from IMS Health (Market 
Sizing). Equivalence of the 3 BoNTAs in terms of efficacy and safety is assumed and 
therefore no differential use of medical services or other goods. Results: Annual 
BoNT-A drug costs per ULS patient were 3 463€ , 5 603€ , and 5 410€ , respectively, 
with prescribing patterns following SmPC recommendations for abobotulinum-
toxinA, onabotulinumtoxinA, and incobotulinumtoxinA. The total drug costs were 
decreased by between 1 231 861€ (-4%) in year 2 and 5 133 684€ (-17%) in year 5 by 
shifting the market share to abobotulinumtoxinA. Sensitivity analyses showed that 
the number of patients treated with BoNT-As, time to re-injection, and dose per 
injection were the most influential parameters on budget impact, impacting both 
drug acquisition costs and physician visits. cOnclusiOns: Increased use of abo-
botulinumtoxinA compared with incobotulinumtoxinA and onabotulinumtoxinA 
for ULS in Germany could potentially reduce the total cost of treatment.
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Objectives: Renal denervation (RDN) is a new treatment option for patients with 
uncontrolled resistant hypertension. Studies have shown RDN to have a potential 
reduction in systolic blood pressure and therefore reduce risk for different cerebro-
cardiovascular disease (stroke, ischemic heart disease, heart failure, etc.). The aim is 
to assess the economic impact of renal denervation in resistant hypertensive patients 
based on the potential clinical benefit demonstrated in literature. MethOds: 
A budget impact model was developed to quantify RDN-related cost-savings accom-
plished through lower rate of cerebro-cardiovascular events compared with the 
medical treatment cohort (with 3+ anti-hypertensive medications including a diu-
retic). The model was developed from the Italian National Healthcare Service (NHS) 
perspective with a 10-year time horizon. The risk of events was calculated using 
different multivariate equations. A literature review was carried out to collect the 
treatment costs for both acute and chronic phase of hypertension-related events. 
The cost of RDN procedure was approximated to the related DRG tariff. Results: 
Renal denervation, considering the blood pressure reduction observed after pro-
cedure, substantially reduces cerebro-cardiovascular event probabilities by 30% if 
compared to the medical treatment cohort. Assuming a yearly 2% RDN adoption 
rate, approximately 2,000 events would be avoided in 10 years allowing total savings 
up to 9 Million euro. The higher cost of new technology was offset from potential 
saving associated to the avoided events. Compared to the total costs associated 
to the medical treatment cohort in 10 years the overall expenditure for RDN was 
greater than 0.8%. The annual incremental cost for patients treated with surgical 
approach was estimated at 16 euro per patient. cOnclusiOns:  The economic 
impact of hypertension-related complications is significant in the Italian setting. 
Consequently the potential savings according to the NHS perspective derived from 
the implementation of strategies aimed at improving the level of hypertension 
should be considered.
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Objectives: To estimate the costs associated with the use of dabigatran (DB) vs. 
dicoumarins (DC) in non-valvular atrial fibrillation (NVAF) from the perspective 
of the Extremadura Public Health System (EPHS) in 2013. MethOds: A budget 
impact study of anticoagulant therapy (AT) with DB and DC in patients with NVAF 
was carried out during 2013. The data were processed using the JARA® electronic 
record application. Pharmaceutical costs and costs associated with patient follow-
up and monitoring were included. Costs relating to incidence of stroke, gastroin-
testinal bleeding, intracranial haemorrhage and acute myocardial infarction were 
also included based on RE-LY clinical trials. For pharmaceutical cost RRP + VAT of 
the medicinal products was used, and other health care costs were based on the 
public prices of the EPHS and the National Health System. Results: Three hun-
dred eighty-five patients were treated with DB (4.01 %) and 8876 with DC (92.63%). 
Mean age was 77 (95 % CI: 76.82-77.19). Total expenditure for AT with AVK for the 
best case scenario would be € 3,036,604.28 (mean cost per patient: € 342.11; 95% 
CI: 341.80-342.34) and the worst case € 3,727,169.83 (€ 419.92; 95% CI: 419.70-419.15) 
and for DB € 318,077.15 (mean expenditure: € 826.27; 95% CI: 796.81-855.57). For a 
DB market penetration of 50%, expenditure on anticoagulation of these patients 
would be € 3,958,659.57 while for 75% it would be € 5,937,989.36. cOnclusiOns: 
Dabigatran is a more costly option than classic treatment with DC. In 2013 this drug’s 
market penetration was limited and was closer to other estimates. Estimated mean 
cost per patient for DCs is similar to the estimates of other communities (Basque 
Country: € 300-700 and the Valencian Community: € 300) and are somewhat lower 
for DB (Basque Country: € 1,197 and the Valencian Community: € 1,350). A limitation 
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and after excluding the outliers and longer than 90 days LOS, the data included 
3,428 patients. The estimated mean difference using the average CMG+ estimate 
for the whole hospital episode costs were about $500 higher than actual costs. The 
median CMG+ cost were most accurate estimates for per diem costs, which was 
about $20 higher than actual cost. 2 comorbidities were dropped from the regression 
due to multicollinearity. Using average CMG+ estimate for whole hospital episode 
costs, 10/13 comorbidity coefficients were found to be statistically equivalent to the 
coefficients in a separate regression using actual cost. cOnclusiOns: This study 
shows that various derivations of costing proxies using the CMG+ methodology 
produce relatively accurate cost estimates for AMI patients when actual cost are 
not available. Based on the available patient data and the context of use of the cost 
estimates, different methods will be optimal.
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COmBinEd OffiCE and amBulatOry mEasurEmEnts in hyPErtEnsiOn 
managEmEnt
Boubouchairopoulou N.1, Karpettas N.2, Athanasakis K.1, Kollias A.2, Protogerou A.D.3, 
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Objectives: Hypertension is a chronic condition, directly linked to cardiovascular 
diseases. Therefore, the monitoring of blood pressure (BP) is of utmost importance in 
order to avoid BP-related adverse clinical outcomes. This study aimed at comparing 
the health resources consumed and the subsequent costs for hypertension man-
agement using home blood pressure monitoring alone (HBPM) vs combined office 
measurements and ambulatory blood pressure monitoring (C/ABPM). MethOds: 
A total of 116 previously untreated, hypertensive subjects were randomized to use 
either HBPM or C/ABPM for antihypertensive treatment initiation and titration. The 
analysis involved all health resources (BP measurements/outpatient visits, labora-
tory and other tests, pharmaceutical therapy) utilized within 12-months follow up, 
their respective costs, and efficacy (hypertension control). A 5-year projection was 
applied assuming (a) continuation of stable treatment as in the end of first year (for 
both arms), (b) single ABPM/year in C/ABPM group, (c) 2 visits/year in HBPM group 
and 3 in ABPM. Results: The total cost of hypertension management regardless 
of BP measurement method was calculated at 1,404.8€ /patient (laboratory tests: 
50.4%, BP measurements+outpatient visits: 32.4%, pharmaceuticals: 17.1%). In HBPM 
group, total cost was 1,336.0€ /patient vs 1,473.5€ /patient in C/ABPM group (p< 0.001). 
Findings suggested that the cost of treatment did not differ between the two groups 
(233.1 vs 247.6€ /patient respectively, p= NS), while BP measurements+outpatient vis-
its were estimated at 393.9€ /patient in HBPM arm and 516.9€ /patient in C/ABPM arm 
(p< 0.001). For subsequent years (> 1), expenditures were estimated at 348.9€ /patient 
for HBPM vs 440.2€ /patient for C/ABPM group (p< 0.001), whereas for a 5-year projec-
tion, 2,731.4€ /patient and 3,234.3€ /patient respectively (p< 0.001). cOnclusiOns: 
C/ABPM strategy presented a higher first year cost compared to HBPM, while the 
same trend was unveiled in 5-year projection. Effective hypertension management 
through the appropriate strategies is of paramount importance considering its high 
prevalence; ergo, even small differences in the cost of applying them could have 
substantial impact on health expenditures.
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Objectives: Literature has failed to demonstrate the clear superiority of Drug-Eluting 
Stenting (DES) for stable coronary artery diseases on survival as compared to the bare-
metal stenting (BMS). This study aimed to compare the health care utilization and 
the costs between drug-eluting stenting (DES) and bare-metal stenting (BMS). We also 
examined factors that influenced cumulative costs of these two groups. MethOds: 
We conducted a retrospective cohort study based on the NHI program. Patients who 
had coronary stenting between Jan. 2007 and Dec. 2008 were recruited and followed 
through the end of 2010. Both groups were matched on 2: 1 by propensity score which 
adjusted sex, age, stent number and Charlson comorbidity index (CCI). We estimated 
cumulative medical cost for these two matched group by conducting the Kaplan-
Meier Sample Average (KMSA) estimates. Regression analysis was used to explore the 
predictors of cost. Results: The mean age in both groups was around 66 years. After 
propensity score matching, we had a total of 966 patients; 644 in BMS group and 322 
in DES group. KMSA estimates (discounted 3.5%) showed that DES group had a higher 
3-year cumulative total outpatient cost at US$ 6,867 and heart related outpatient 
cost at US$ 2,548 as compared to BMS group, which were US$7,668 and US$ 3,302 
respectively (1US$= 30 NTD). The heart related inpatient cost was similar between two 
groups. The significant predictors of heart-related outpatient costs were stent type, 
premium and CCI. The predictors of heart-related inpatient costs were stent type, 
stent number, CCI and procedure for acute coronary syndrome (ACS). cOnclusiOns: 
In Taiwan, NHI reimburses DES and BMS at the same price, and hospitals can balance 
billing for the DES. We found that even after adding the extra national average out-
of-pocket payment to DES, DES still was a cost-effective procedure.
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gOal dirECtEd PErfusiOn (gdP): a diffErEntial COst analysis in uk 
and us
Povero M., Pradelli L.
AdRes HE&OR, Turin, Italy
Objectives: High oxygen delivery (DO2) during cardiopulmonary bypass (CPB) 
is associated with better renal outcome in cardiac surgery. Traditional perfusion 
(TP) techniques, targeted on body surface area and CPB temperature, achieves high 
DO2 in about 50% of the cases while a goal directed perfusion (GDP) approach can 
lead to more than 90% of cases achieving high DO2 with a consequent reduction 
priate anticoagulation are recognised, but full implementation can be difficult and 
costly. Therefore the development of models such as this can support the planning 
process allowing stakeholders to discuss how best they can reach the target of full 
implementation. The model is flexible and can be adapted to suit different payers.
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Objectives: Mitral Regurgitation (MR) is a cardiac disease resulting in backflow 
of blood from the left ventricle to the left atrium which could increase the risk of 
heart failure and mortality. Half of severe MR patients are not considered eligi-
ble to surgery (valve repair or replacement) and receive a medical treatment. MR 
patient management could benefit from usage of Mitraclip, a transcatheter device, 
which enables percutaneous edge-to-edge repair to treat MR. The cost-effectiveness 
model presented here compares Mitraclip therapy versus medical standard care 
treatment. MethOds: A four-state Markov model (Death, MR grade 0, MR grade I 
/II, MR grade III/ IV) has been developed. In each state patients could be hospital-
ized or not. A national payer’s perspective was chosen with a 5 year time horizon. 
Primary and secondary endpoints were respectively the number of deaths and of 
hospitalizations avoided. Data were obtained from the EVEREST II high-risk study 
and from french cost analysis. Results: Within the time horizon analyzed, 276 
further deaths could be avoided by using Mitraclip strategy out of 1000 patients 
with MR, compared to medical treatment. The Incremental Cost Effectiveness Ratio 
(ICER) is estimated at € 93,000 per death averted with cumulative cost on five years. 
Sensitivity analysis shows that the cost of the initial surgery and the cost of the 
device where the two most sensitive variables. Costs of managing MR are higher for 
the Mitraclip option during the first year (€ 29,894 for Mitraclip compared to € 8,557 
for medical treatment) option due to the cost of the device and surgery, whereas 
this is inversed from the second year onwards (€ 8,557 for the medical option vs. 
€ 3,122 for Mitraclip). Therefore, an average ICER (20 720€ per death averted) has also 
been calculated. cOnclusiOns: Mitraclip might represent a new economically 
attractive treatment option for MR patients at high-risk which increases survival.
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Objectives: 1) Analyze whether a testing strategy using the biomarker 
Lp-PLA2would improve clinical and economic outcomes vs. ESC-SCORE alone in 
Germany for 50-70 year-olds. 2) Evaluate the potential budget impact for payers.  
MethOds: To decide the treatment strategy for patients with moderate risk for 
cardiovascular events is a challenge. They would usually not receive statin treat-
ment in Germany. For further risk stratification there is a need to identify patients 
with vulnerable plaques. When an arterial plaque becomes unstable Lp-PLA2is 
released, which indicate that these patients could benefit from treatment to pre-
vent future cardiovascular events. An integrated cost-effectiveness and budget 
impact model was constructed. Lp-PLA2increased the adjusted risk for CVD events 
in the moderate ESC-SCORE population by > 2 fold in the German LURIC Study 
Cohort (HR 2.23,95% CI 1.15-4.32; P= 0.018). Efficacy of statin treatment relevant 
costs were obtained from literature. A range of sensitivity analyses were per-
formed. Results: The cost-effectiveness and the budget impact analyses used a 
theoretical population of 1 million, of which 14% were 50-70 year olds with mod-
erate cardiovascular risk. The total 10-year discounted and adherence adjusted 
net cost savings from implementing the Lp-PLA2 testing strategy was € 19 million, 
or € 156 per Lp-PLA2tested patient. The 10-year accumulated number of deaths 
averted by the Lp-PLA2 testing strategy was 611, or 17 incremental discounted 
life-days and 2.2 incremental discounted event-free life-months per Lp-PLA2tested 
patient. Projected to whole of Germany’s population aged 50-70 the potential 
annual discounted savings from the Lp-PLA2testing strategy would be € 180 million. 
The potential number of deaths averted per year would be 5,030. cOnclusiOns: 
Our results indicate that the Lp-LPA2 testing strategy is both cost saving and pro-
vide reduction in mortality and morbidity. The implementation of Lp-LPA2 testing 
strategy should be considered in Germany.
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Objectives: This study compares differences in actual hospital costs and Case 
Mixed Group (CMG+) costs (Canadian version of the Diagnosis Related Group), for 
patients with acute myocardial infarction (AMI) in Edmonton, Alberta. MethOds: 
New AMI (ICD-10 code I21) patients (no AMI hospitalization within one year) hos-
pitalized in Edmonton area hospitals between April 1,2006 and March 30,2009 were 
segmented into CMG+ categories by the Canadian Institute for Health Information. 
The differences between actual hospital cost and CMG+ cost were analyzed by com-
paring the mean and median differences between costs for each patient and trim-
ming out 5% of high and low cost patients and excluding patients with longer than 
90 days of hospitalization. 15 comorbidities were derived from secondary diagnostic 
codes and regressed against CMG+ costs and actual costs independently. The coef-
ficients between the two separate regressions are then tested for statistical equiva-
lence using the Wald test. Results: The data included 4,734 new AMI patients, 
